The German AML Cooperative Group is inviting all experts to participate in the 16th International Symposium on Acute Leukemias (ISAL) which will be held in Munich, Germany on 19–22 February, 2017.

The scientific program will focus on basic research in acute leukemia while the following days of the meeting will concentrate on translational research and clinical studies.

ISAL 2017

The 16th International Symposium on Acute Leukemias (ISAL)
19–22 February 2017 | Munich, Germany

ISAL 2017

The 16th International Symposium on Acute Leukemias (ISAL)
19–22 February 2017 | Munich, Germany

The German AML Cooperative Group is inviting all experts to participate in the 16th International Symposium on Acute Leukemias (ISAL) which will be held in Munich, Germany on 19–22 February, 2017.

The scientific program will focus on basic research in acute leukemia while the following days of the meeting will concentrate on translational research and clinical studies.

Hereditary leukemias – clinical implications 1:59
Hereditary leukemias – clinical implications
Jane Churpek • 24 Feb 2017
Do gene mutations impact clinical outcome in elderly acute myeloid leukemia (AML) patients? 2:33
Do gene mutations impact clinical outcome in elderly acute myeloid leukemia (AML) patients?
Victoria Prassek • 24 Feb 2017
Revisiting clinical trial design – more adaptability in Phase I – III? 4:52
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey • 24 Feb 2017
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC 6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017
Advances in acute myeloid leukemia (AML) treatment – updating 7+3 2:24
Advances in acute myeloid leukemia (AML) treatment – updating 7+3
Utz Krug • 24 Feb 2017
The Society of Hematologic Oncology (SOHO) 2:34
The Society of Hematologic Oncology (SOHO)
Hagop Kantarjian • 20 Feb 2017
Trials of BiTEs for the treatment of acute leukemias 2:49
Trials of BiTEs for the treatment of acute leukemias
Ralf Bargou • 24 Feb 2017
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance 3:16
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance
Rafael Bejar • 24 Feb 2017
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers 2:01
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval Daver • 24 Feb 2017
Clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (AML) 1:20
Clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (AML)
Klaus Metzeler • 24 Feb 2017
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics 5:39
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics
Charles Mullighan • 24 Feb 2017
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)? 1:11
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Felicitas Thol • 24 Feb 2017
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized? 1:33
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Utz Krug • 24 Feb 2017
Clinically relevant side effects of BiTE immunotherapy and other T-cell therapies 1:08
Clinically relevant side effects of BiTE immunotherapy and other T-cell therapies
Ralf Bargou • 24 Feb 2017
Studying the evolution of acute myeloid leukemia (AML) relapse 3:21
Studying the evolution of acute myeloid leukemia (AML) relapse
Philipp Greif • 24 Feb 2017
Clinical trials of immune checkpoint inhibitors in acute myeloid leukemia (AML) 2:11
Clinical trials of immune checkpoint inhibitors in acute myeloid leukemia (AML)
Naval Daver • 24 Feb 2017

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals